Polyarteritis nodosa epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Sargun Walia (talk | contribs) |
Sargun Walia (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The [[incidence]] of PAN is approximately 3 to 4 per 100,000 individuals worldwide.<ref name="pmid2562798">{{cite journal |vauthors=McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP |title=Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up |journal=Hepatology |volume=9 |issue=1 |pages=97–101 |date=January 1989 |pmid=2562798 |doi= |url=}}</ref> | |||
*The incidence | |||
===Prevalence=== | ===Prevalence=== | ||
*The [[prevalence]] among alaskan population suffering with [[hepatitis B]] infection is approximately 7.7 per 100,000 individuals. | |||
*The | |||
===Age=== | ===Age=== | ||
*Patients of all age groups may develop PAN. | |||
*Patients of all age groups may develop | *PAN is mostly diagnosed in patients aged 45-65 years. <ref name="pmid16045832">{{cite journal |vauthors=Colmegna I, Maldonado-Cocco JA |title=Polyarteritis nodosa revisited |journal=Curr Rheumatol Rep |volume=7 |issue=4 |pages=288–96 |date=August 2005 |pmid=16045832 |doi= |url=}}</ref> | ||
* | |||
===Race=== | ===Race=== | ||
*There is no racial predilection to PAN. | |||
*There is no racial predilection to | |||
===Gender=== | ===Gender=== | ||
*Males are more commonly affected by PAN than females. The male to female ratio is approximately 1.5 to 1. | |||
* | |||
=== Region === | |||
* Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries <ref name="pmid17553910">{{cite journal| author=Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M| title=Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. | journal=Rheumatology (Oxford) | year= 2007 | volume= 46 | issue= 8 | pages= 1329-37 | pmid=17553910 | doi=10.1093/rheumatology/kem107 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17553910 }} </ref> | |||
* The annual incidence in three regions of Europe was estimated to be 4.4 to 9.7 per million <ref name="pmid10693883">{{cite journal| author=Watts RA, Lane SE, Bentham G, Scott DG| title=Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. | journal=Arthritis Rheum | year= 2000 | volume= 43 | issue= 2 | pages= 414-9 | pmid=10693883 | doi=10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10693883 }} </ref>. | |||
==References== | ==References== | ||
Revision as of 14:06, 11 May 2018
|
Polyarteritis nodosa Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polyarteritis nodosa epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polyarteritis nodosa epidemiology and demographics |
|
Polyarteritis nodosa epidemiology and demographics in the news |
|
Risk calculators and risk factors for Polyarteritis nodosa epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]
Overview
Epidemiology and Demographics
Incidence
Prevalence
- The prevalence among alaskan population suffering with hepatitis B infection is approximately 7.7 per 100,000 individuals.
Age
- Patients of all age groups may develop PAN.
- PAN is mostly diagnosed in patients aged 45-65 years. [2]
Race
- There is no racial predilection to PAN.
Gender
- Males are more commonly affected by PAN than females. The male to female ratio is approximately 1.5 to 1.
Region
- Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries [3]
- The annual incidence in three regions of Europe was estimated to be 4.4 to 9.7 per million [4].
References
- ↑ McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP (January 1989). "Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up". Hepatology. 9 (1): 97–101. PMID 2562798.
- ↑ Colmegna I, Maldonado-Cocco JA (August 2005). "Polyarteritis nodosa revisited". Curr Rheumatol Rep. 7 (4): 288–96. PMID 16045832.
- ↑ Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden". Rheumatology (Oxford). 46 (8): 1329–37. doi:10.1093/rheumatology/kem107. PMID 17553910.
- ↑ Watts RA, Lane SE, Bentham G, Scott DG (2000). "Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom". Arthritis Rheum. 43 (2): 414–9. doi:10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0. PMID 10693883.